Key result
Anti-Ro/La testing is clinically indicated in ~55% of screened pregnant women, reducing unnecessary fetal surveillance.
Why the study?
To evaluate current anti-Ro and anti-La autoantibody ordering patterns, clinical indications for performing these tests, and potential cost-benefit analysis.
Cohort (n=47)
No
Anti-Ro/La autoantibody testing in pregnant women is largely performed according to guidelines, and identifying negative patients yields economic benefits by reducing unnecessary fetal heart surveillance.
Minimal cost-benefit of anti-Ro/La testing cautions against routine use; leaves open refined indications for congenital heart block screening.
OBJECTIVES: To evaluate current anti-Ro and anti-La autoantibody ordering patterns, clinical indications for performing these tests, and potential cost-benefit analysis. METHODS: In this retrospective cohort study, patients who underwent autoantibody testing over 1 year were included. Necessary information was obtained from patient electronic records. RESULTS: In total 47 patients underwent anti-Ro/La autoantibody testing. Of those tested, 11/47 (2%) had positive results and testing was clinically indicated in 26/47 (55%) patients, indicating minimal cost-benefits. The total rate of the cost prescription was €1644.96. The mean time to process tests was 5 days. In those with positive autoantibodies, two infants were diagnosed with congenital heart block and had pacemakers inserted after delivery. CONCLUSION: This study found anti-Ro/La autoantibody tests were appropriately ordered in accordance with clinical guidelines. By identifying patients who were autoantibody negative, economic benefits were gained, in terms of antenatal management including reduced frequency of antenatal visits and fetal heart surveillance.
No takes yet. Share an insight, caveat, or question.
Tunney et al. (2025) conducted a cohort in Pregnancy with indication for anti-Ro/La autoantibody screening (n=47). Anti-Ro/La autoantibody testing was evaluated on Clinical indication for anti-Ro/La autoantibody testing. Anti-Ro/La autoantibody testing was clinically indicated in 55% of screened pregnant women, with 23% testing positive, allowing for targeted management and reduced unnecessary fetal surveillance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: